摘要
乳腺癌的发病率位居全球女性恶性肿瘤首位,其中激素受体阳性且人表皮生长因子受体2阴性(HR+/HER2-)乳腺癌是最常见的亚型.内分泌治疗是HR+/HER2-晚期乳腺癌(ABC)主要的治疗方式之一.近年来,针对晚期HR+/HER2-ABC的内分泌治疗研究取得了重要的进展,从选择性雌激素受体调节剂到芳香化酶抑制剂,再到选择性雌激素受体降解剂,不断丰富着HR+/HER2-ABC内分泌治疗的选择.近年来,多种靶向治疗药物相继问世,包括周期蛋白依赖性激酶4/6抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂、磷脂酰肌醇-3-激酶抑制剂等使得内分泌联合靶向治疗备受关注.这些新药的应用显著改善了患者的生存和生活质量,为患者提供了更多的治疗选择.随着这些新药的研发和问世,HR+/HER2-ABC的内分泌治疗已进入了一个靶向联合治疗新时代.文章对HR+/HER2-ABC的内分泌治疗研究进展进行综述,旨在优化HR+/HER2-ABC的治疗选择.
Breast cancer is the most common malignancy among women worldwide.Hormone receptor-positive and human epidermal growth factor receptor 2-negative(HR+/HER2-)breast cancer represents the most prevalent subtype.Endocrine therapy is a primary therapeutic approach for HR+/HER2-advanced breast cancer(ABC).In recent years,substantial advancements have been achieved in the field of endocrine therapy for HR+/HER2-ABC,encompassing selective estrogen receptor modulators,aromatase inhibitors,and selective estrogen receptor degraders,thereby expanding the range of treatment options available for HR+/HER2-ABC.Additionally,a variety of targeted therapeutic drugs,including cyclin-dependent kinase 4/6 inhibitors,mammalian target of rapamycin inhibitors,and phosphoinositide-3 kinase inhibitors,have garnered considerable attention for their potential in combination with endocrine therapy.The utilization of these novel drugs has significantly improved patient survival and quality of life,providing patients with more treatment options.With the advent and implementation of these novel drugs,the era of targeted combination therapy for HR+/HER2-ABC has commenced.This review aims to summarize the research progress of endocrine therapy for HR+/HER2-ABC and optimize treatment selection for this subtype.
作者
陈海珠
姚和瑞
Chen Haizhu;Yao Herui(Breast Tumor Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120)
出处
《中国肿瘤临床与康复》
2023年第3期180-191,共12页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
晚期乳腺癌
激素受体阳性
人表皮生长因子受体2阴性
内分泌治疗
Advanced breast cancer
Hormone receptor-positive
Human epidermal growth factor receptor 2-negative
Endocrine therapy
